Iovance Biotherapeutics (IOVA) Short Interest Ratio & Short Volume $5.78 +0.17 (+3.03%) Closing price 04:00 PM EasternExtended Trading$5.80 +0.02 (+0.35%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Iovance Biotherapeutics Short Interest DataIovance Biotherapeutics (IOVA) has a short interest of 63.91 million shares, representing 26.04% of the float (the number of shares available for trading by the public). This marks a 3.11% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.8, indicating that it would take 7.8 days of the average trading volume of 8.53 million shares to cover all short positions.Current Short Interest63,910,000 sharesPrevious Short Interest61,980,000 sharesChange Vs. Previous Month+3.11%Dollar Volume Sold Short$373.87 millionShort Interest Ratio7.8 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares304,780,000 sharesFloat Size245,470,000 sharesShort Percent of Float26.04%Today's Trading Volume10,872,857 sharesAverage Trading Volume8,530,101 sharesToday's Volume Vs. Average127% Short Selling Iovance Biotherapeutics? Sign up to receive the latest short interest report for Iovance Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIOVA Short Interest Over TimeIOVA Days to Cover Over TimeIOVA Percentage of Float Shorted Over Time Iovance Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/202563,910,000 shares $373.87 million +3.1%26.0%7.8 $5.85 1/15/202561,980,000 shares $366.30 million +1.1%25.1%8.1 $5.91 12/31/202461,310,000 shares $453.69 million +3.3%24.8%8.9 $7.40 12/15/202459,330,000 shares $464.55 million +4.2%24.0%9.6 $7.83 11/30/202456,920,000 shares $530.49 million +5.4%23.1%9.3 $9.32 11/15/202453,990,000 shares $441.64 million -9.6%21.9%8.6 $8.18 10/31/202459,730,000 shares $623.58 million -1.0%24.1%10.2 $10.44 10/15/202460,340,000 shares $578.66 million +0.7%24.4%10.1 $9.59 9/30/202459,950,000 shares $562.93 million -0.6%24.3%9.7 $9.39 9/15/202460,290,000 shares $623.40 million +4.5%24.4%8.9 $10.34 Get the Latest News and Ratings for IOVA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202457,690,000 shares $672.67 million -2.8%23.3%8 $11.66 8/15/202459,330,000 shares $633.05 million -3.3%24.5%8 $10.67 7/31/202461,320,000 shares $535.32 million +4.0%27.4%8.3 $8.73 7/15/202458,940,000 shares $511.60 million +4.5%26.4%9 $8.68 6/30/202456,420,000 shares $452.49 million +3.3%25.2%9 $8.02 6/15/202454,630,000 shares $445.78 million +9.4%24.4%9.3 $8.16 5/31/202449,960,000 shares $443.64 million -2.4%22.3%8.5 $8.88 5/15/202451,210,000 shares $546.92 million +2.3%22.9%7.8 $10.68 4/30/202450,060,000 shares $589.71 million +2.2%22.6%5.7 $11.78 4/15/202448,980,000 shares $582.37 million +5.6%22.2%5.5 $11.89 3/31/202446,380,000 shares $687.35 million -2.2%21.1%4.9 $14.82 3/15/202447,430,000 shares $659.75 million +1.5%21.6%4.6 $13.91 2/29/202446,710,000 shares $743.16 million +8.7%21.2%4.5 $15.91 2/15/202442,980,000 shares $424.21 million +2.4%20.1%4.4 $9.87 1/31/202441,970,000 shares $324.43 million -3.0%21.0%5.6 $7.73 1/15/202443,270,000 shares $389.86 million +18.8%21.7%5.7 $9.01 12/31/202336,410,000 shares $296.01 million +3.2%18.2%4.8 $8.13 12/15/202335,280,000 shares $274.48 million +2.0%17.7%5.1 $7.78 11/30/202334,590,000 shares $209.96 million -2.8%17.5%4.7 $6.07 11/15/202335,590,000 shares $169.05 million -8.4%18.0%5.2 $4.75 10/31/202338,860,000 shares $148.45 million +0.3%19.4%6 $3.82 10/15/202338,740,000 shares $140.63 million +5.4%19.4%6.4 $3.63 9/30/202336,770,000 shares $167.30 million +20.5%18.4%6 $4.55 9/15/202330,510,000 shares $160.79 million +1.5%15.3%4.9 $5.27 8/31/202330,070,000 shares $181.62 million +9.2%14.7%6.2 $6.04 8/15/202327,530,000 shares $206.75 million -0.1%13.5%4.6 $7.51 7/31/202327,550,000 shares $200.01 million +6.1%13.6%4.6 $7.26 7/15/202325,960,000 shares $201.45 million -10.1%13.1%4.4 $7.76 6/30/202328,890,000 shares $203.39 million +12.8%14.6%5.1 $7.04 6/15/202325,620,000 shares $221.36 million +18.3%14.1%4.8 $8.64The FED is losing the war on inflation (Ad)It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…You can go here to give yourself a head start. 5/31/202321,650,000 shares $189.22 million -7.4%11.9%4.4 $8.74 5/15/202323,380,000 shares $183.30 million No Change12.9%5.9 $7.84 10/31/202217,260,000 shares $161.21 million -5.0%12.2%8 $9.34 10/15/202218,170,000 shares $160.80 million -2.6%12.7%8.2 $8.85 9/30/202218,660,000 shares $178.76 million -4.5%13.0%8 $9.58 9/15/202219,540,000 shares $231.94 million -0.6%13.7%6.5 $11.87 8/31/202219,650,000 shares $210.65 million -5.4%13.7%5.6 $10.72 8/15/202220,760,000 shares $266.77 million +6.9%14.5%4.1 $12.85 7/31/202219,420,000 shares $226.24 million -2.6%14.0%3.8 $11.65 7/15/202219,940,000 shares $255.23 million -7.5%14.3%4.1 $12.80 6/30/202221,550,000 shares $237.91 million +30.1%15.5%4.4 $11.04 6/15/202216,560,000 shares $135.79 million -4.7%11.9%3.5 $8.20 5/31/202217,370,000 shares $117.25 million +1.0%12.5%4.6 $6.75 5/15/202217,200,000 shares $242.00 million +8.8%12.4%8.2 $14.07 4/30/202215,810,000 shares $239.52 million +3.7%11.4%7.7 $15.15 4/15/202215,250,000 shares $268.71 million +9.9%11.0%7.3 $17.62 3/31/202213,880,000 shares $231.10 million +1.5%N/A6.3 $16.65 3/15/202213,680,000 shares $171.14 million -0.3%9.9%6.7 $12.51 2/28/202213,720,000 shares $214.99 million +9.4%10.1%7 $15.67 2/15/202212,540,000 shares $223.96 million +11.6%9.2%6.3 $17.86 1/31/202211,240,000 shares $187.15 million -6.5%8.3%5.3 $16.65 1/15/202212,020,000 shares $186.19 million -3.6%N/A5.7 $15.49 12/31/202112,470,000 shares $238.05 million -6.9%9.1%6.7 $19.09 12/15/202113,390,000 shares $247.85 million -14.3%9.8%7.9 $18.51 11/30/202115,620,000 shares $292.41 million -1.1%11.5%9.5 $18.72 11/15/202115,800,000 shares $309.52 million +3.7%11.6%10.2 $19.59 10/29/202115,230,000 shares $370.24 million +0.3%11.1%11.2 $24.31 10/15/202115,190,000 shares $404.21 million +3.8%11.2%11.2 $26.61 9/30/202114,640,000 shares $361.02 million -5.5%10.8%10 $24.66 9/15/202115,490,000 shares $372.22 million -6.7%11.5%9.4 $24.03 8/31/202116,600,000 shares $399.56 million -2.0%12.3%9 $24.07 8/13/202116,940,000 shares $368.78 million -1.7%12.5%7.5 $21.77 7/30/202117,240,000 shares $383.93 million -3.5%12.7%4.8 $22.27 7/15/202117,860,000 shares $402.39 million +0.7%12.7%4.9 $22.53 6/30/202117,730,000 shares $461.33 million -14.4%12.6%4.8 $26.02 6/15/202120,720,000 shares $490.65 million -7.2%14.7%5.5 $23.68 5/28/202122,330,000 shares $414.67 million +11.0%15.9%6.1 $18.57 5/14/202120,120,000 shares $503.20 million +1.9%N/A5.8 $25.01 4/30/202119,750,000 shares $618.97 million -1.5%N/A9.7 $31.34 4/15/202120,040,000 shares $601.00 million -6.0%N/A10.8 $29.99 3/31/202121,320,000 shares $631.92 million +43.3%N/A12 $29.64 3/15/202114,880,000 shares $516.19 million +6.4%N/A10.1 $34.69 2/26/202113,980,000 shares $510.41 million +9.4%N/A10 $36.51 2/12/202112,780,000 shares $610.25 million -9.0%N/A10.3 $47.75 1/29/202114,050,000 shares $613.28 million -8.4%N/A11.7 $43.65 1/15/202115,340,000 shares $798.14 million -1.2%N/A12.8 $52.03 12/31/202015,530,000 shares $757.24 million -5.4%N/A12 $48.76 12/15/202016,410,000 shares $824.77 million -2.2%N/A10.9 $50.26 11/30/202016,780,000 shares $660.80 million +1.3%N/A12.1 $39.38 11/15/202016,570,000 shares $625.02 million -0.1%N/A11.7 $37.72Nvidia > DeepSeek (Ad)Everyone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long run … that's a good thing.Click here to see why Nvidia's bad day could end up being a great year. 10/30/202016,590,000 shares $595.25 million +9.4%N/A11.9 $35.88 10/15/202015,160,000 shares $524.54 million +17.3%N/A10.9 $34.60 9/30/202012,920,000 shares $425.33 million -7.0%N/A10.2 $32.92 9/15/202013,890,000 shares $496.15 million -4.6%N/A10.4 $35.72 8/31/202014,560,000 shares $485.28 million +1.0%N/A10 $33.33 8/14/202014,410,000 shares $400.45 million +3.2%N/A8 $27.79 7/31/202013,960,000 shares $405.82 million -2.4%11.9%7.3 $29.07 7/15/202014,300,000 shares $431.00 million -2.3%12.2%6.9 $30.14 6/30/202014,640,000 shares $398.35 million -1.2%12.5%6.7 $27.21 6/15/202014,810,000 shares $443.56 million +3.7%12.7%7.1 $29.95 5/29/202014,280,000 shares $458.25 million +4.1%12.2%6.6 $32.09 5/15/202013,720,000 shares $485.28 million -0.5%11.7%6.3 $35.37 4/30/202013,790,000 shares $443.35 million -2.3%11.9%6.6 $32.15 4/15/202014,120,000 shares $494.76 million +3.7%12.2%7.3 $35.04 3/31/202013,620,000 shares $502.71 million +6.2%11.8%7.2 $36.91 3/13/202012,825,400 shares $408.87 million -11.9%11.1%5.8 $31.88 2/28/202014,560,000 shares $346.67 million +3.6%12.6%9.3 $23.81 IOVA Short Interest - Frequently Asked Questions What is Iovance Biotherapeutics' current short interest? Short interest is the volume of Iovance Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 63,910,000 shares of IOVA short. 26.04% of Iovance Biotherapeutics' shares are currently sold short. Learn More on Iovance Biotherapeutics' current short interest. What is a good short interest ratio for Iovance Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IOVA shares currently have a short interest ratio of 8.0. Learn More on Iovance Biotherapeutics's short interest ratio. Which institutional investors are shorting Iovance Biotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Iovance Biotherapeutics: Wolverine Trading LLC, Group One Trading LLC, Caption Management LLC, Cantor Fitzgerald L. P., Citadel Advisors LLC, Jane Street Group LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., Walleye Trading LLC, Walleye Capital LLC, Simplex Trading LLC, and JPMorgan Chase & Co.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Iovance Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 26.04% of Iovance Biotherapeutics' floating shares are currently sold short. Is Iovance Biotherapeutics' short interest increasing or decreasing? Iovance Biotherapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 63,910,000 shares, an increase of 3.1% from the previous total of 61,980,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Iovance Biotherapeutics' float size? Iovance Biotherapeutics currently has issued a total of 304,780,000 shares. Some of Iovance Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Iovance Biotherapeutics currently has a public float of 245,470,000 shares. How does Iovance Biotherapeutics' short interest compare to its competitors? 26.04% of Iovance Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Iovance Biotherapeutics: Legend Biotech Co. (6.92%), BridgeBio Pharma, Inc. (12.66%), Axsome Therapeutics, Inc. (11.51%), Blueprint Medicines Co. (6.59%), Elanco Animal Health Incorporated (3.36%), Lantheus Holdings, Inc. (10.63%), Nuvalent, Inc. (13.41%), Cytokinetics, Incorporated (12.02%), Verona Pharma plc (10.37%), Grifols, S.A. (1.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Iovance Biotherapeutics stock? Short selling IOVA is an investing strategy that aims to generate trading profit from Iovance Biotherapeutics as its price is falling. IOVA shares are trading up $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Iovance Biotherapeutics? A short squeeze for Iovance Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IOVA, which in turn drives the price of the stock up even further. How often is Iovance Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IOVA, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies LEGN Short Interest BBIO Short Interest AXSM Short Interest BPMC Short Interest ELAN Short Interest LNTH Short Interest NUVL Short Interest CYTK Short Interest VRNA Short Interest GRFS Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IOVA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.